We present here the updated results after 9 years of the beginning of a trial on canine patients with malignant melanoma. This surgery adjuvant approach combined local suicide gene therapy with a subcutaneous vaccine composed by tumor cells extracts and xenogeneic cells producing human interleukin-2 and granulocyte-macrophage colony-stimulating factor. Toxicity was absent or minimal in all patients (0pVCOG-CTCAE gradep1). With respect to surgery-treated controls (ST), the complete surgery (CS) arm of this combined treatment (CT) significantly increased the fraction of local disease-free patients from 13 to 81% and distant metastases free from 32 to 84%. Even though less effective than the CS arm, the partial surgery (PS) arm of this CT was significantly better controlling the disease than only surgery (14% while PS-ST: 0%, Po0.01 and CS-ST: 5%, Po0.05). In addition, CT produced a significant sevenfold (CS) and threefold (PS) increase in overall survival. The CS-CT arm significantly improved both CS-ST metastasis-free-and melanoma overall survival from 99 days (respective ranges: 11-563 and 10-568) to 42848 days (81-2848 and 35-2848). Thus, more of 50% of our CT patients died of melanoma unrelated causes, transforming a lethal disease into a chronic one. Finally, surgery adjuvant CT delayed or prevented post-surgical recurrence and distant metastasis, significantly improved disease-free and overall survival maintaining the quality of life. Long-term safety and efficacy of this treatment are supported by the high number of CT patients (283) and extensive follow-up (49 years). The successful clinical outcome encourages the further translation of similar approaches to human gene therapy trials.
INTRODUCTION
Canine malignant melanoma, a spontaneous and highly aggressive tumor of the oral cavity, digit/footpad and mucocutaneous junctions, appears clinically similar to aggressive human melanoma. Being chemoresistant and radioresistant, both diseases do not respond well to treatment with conventional biological response modifiers and share similar metastatic phenotypes and site selectivity. [1] [2] [3] Like in human melanoma, the prognosis for canine malignant melanoma correlates directly with tumor stage. 3, 4 At the time of diagnosis, the disease is often metastatic and has an extremely poor prognosis because rapid invasion of surrounding normal tissue and high likelihood of regional and distant metastasis early in the course of the disease. [1] [2] [3] [4] [5] As a syngeneic cancer occurring in outbred immune-competent large mammals that live in the same environment than humans, canine malignant melanoma comprises a more clinically faithful therapeutic model for human melanoma when compared with the more traditional mouse/rat systems. [1] [2] [3] We have widely discussed the potential of comparative cancer gene therapy as a preclinical phase for human clinical trials. 5 Different gene therapy approaches have been reported for canine spontaneous melanoma such as: (i) ex vivo human interleukin-2 (hIL-2) producing xenogeneic cells, 6 human granulocytemacrophage colony-stimulating factor (hGM-CSF) producing autologous tumor cells, 7 human gp100 producing allogeneic tumor cells; 8 and (ii) in vivo gene transfer of enterotoxin-B plus GM-CSF, 9 xenogeneic human 10 or murine 11 tyrosinase, human FasL, 12 IL-12 (ref. 13 ) and CD40 ligand. 14 About 80% of the veterinary cancer gene therapy trials on patients with spontaneous tumors could be classified as immunogene therapy and were performed with non-viral vectors. 15 Two emerging approaches are supported by a large number of treated patients: the xenogeneic vaccine developed by Bergman et al., 10 and the suicide gene (SG) plus autologous/ allogeneic vaccine developed by our team. 16 Both systems used as surgery adjuvants, based on the systemic disease control on the immune system. While the first approach using hTyr vaccine was specific for melanoma, 17 the second approach appeared to be more versatile, because a very similar treatment was successfully applied to other kinds of tumors such as soft tissue sarcoma 18 and osteosarcoma. 19 In a previous controlled study, 20 we demonstrated that repeated concurrent injections of the SG system and engineered xenogeneic hIL-2-and hGM-CSF-secreting cells into the tumor bed, substantially controlled tumor growth, and improved diseasefree and overall survival in the treated animals compared with untreated or surgery-treated controls. Taking into account these encouraging data, we designed a treatment adjuvant of surgery against the minimal residual disease whose rationale appeared to be considerably superior to our previous intratumor therapy.
This new treatment consisted of CS or PS. The surgical margin of the cavity after tumor removal was treated with non-viral SG therapy. Then, the patients were treated with a subcutaneous vaccine (SV) composed by autologous or allogeneic formolized tumor cells and irradiated xenogeneic cells producing hIL-2 and hGM-CSF. Patients with local disease (unresectable or partially removed tumor, or post-surgical relapse) received in the remaining tumor multiple injections of SG concurrent with SV. 16 As a continuation of this successful approach, we present here the updated results after 9 years of the beginning of the trial. 16 The new data confirm that the most optimal clinical setting was this surgery adjuvant treatment against minimal residual disease that not only prevented recurrence and the outgrowth of metastases, but also significantly improved disease-free and overall survival while maintaining the quality of life compared with surgery only treated controls.
MATERIALS AND METHODS Cells
Two engineered Chinese hamster ovary cell lines (CHOK1, ATCC no. CCL 61) daily producing about 200 ng hIL-2/10 6 cells and 1500 ng hGM-CSF/10 6 cells, respectively, were generated, cultured, treated and quality assessed as described. 16 
Plasmid
A plasmid carrying the herpes simplex thymidine kinase, psCMVtk (4.5 Kb) was constructed, amplified in E. coli DH5a and quality assessed as described. 16 For injection, plasmid DNA was resuspended to a final concentration of 2.0 mg ml À 1 in sterile phosphate-buffered saline.
Liposome preparation and in vivo lipofection
Liposomes for injection were prepared by combining equimolar amounts of DMRIE (1,2-dimyristyl oxypropyl-3-dimethyl-hydroxyethilammonium bromide, kindly provided by BioSidus SA, Buenos Aires, Argentina) and DOPE (1,2-dioleoyl-sn-glycero-3-phosphatidyl ethanolamine, Sigma, St Louis, MO) as described. 16, 21, 22 Before injection, liposomes and equal amounts of plasmid DNAs (1:2 v-v) were mixed and allowed to combine at room temperature for 10 min. Then, ganciclovir (GCV) (Richet SA, Buenos Aires, Argentina; 5 mg mg À 1 DNA) was added. The mixture was injected intratumorally and/or peritumorally at multiple sites at a final volume of 1-4 ml, depending on tumor size.
Tumor vaccines preparation
Surgically excised tumors were thoroughly chopped, suspended in 10% neutral formaldehyde for 3 days, exhaustively washed with phosphatebuffered saline and homogenized (Ultra-Turrax IKA, Staufen, Germany). Autologous or allogeneic tumor cells preparation were mixed with xenogeneic cytokine producing cells immediately before subcutaneous injection.
Patients
Dogs entered into the study had confirmed histopathological diagnostic of melanoma. The tumors were staged by a veterinary oncologist according to the WHO staging system of stage II (tumors 2-4 cm diameter, negative nodes), stage III (tumor 44 cm and/or positive nodes) or stage IV (distant metastatic disease). All dogs were determined to be free of severe underlying systemic illnesses. During the study, dogs did not receive chemotherapy or another potentially antitumor or immunosuppressive medication. When needed, standard antibiotics, non-steroid anti-inflammatory and/or analgesic medication were administered. The dogs' owners were notified about the experimental nature of the treatment, and all of them granted written informed consent for treatment. Specially trained veterinary professionals, working in accordance with the laws and regulations of our country (Argentina), were involved in clinical follow-up and surgery procedures. All scientific and ethical issues related to the veterinary clinical trial were evaluated and approved by the Academic and Research Committee of the Institute of Oncology (University of Buenos Aires, Argentina).
Study design and treatment
This open-label controlled study involved patients recruited by nine veterinary care centers in Buenos Aires, Argentina. Some owners decided not to follow the intensive gene therapy mostly because of logistics reasons (frequent transportation of the patient) while some of them chose palliative treatments. Patients were assigned accordingly to the patients' owners decision to one of the two main arms designed as surgery plus combined treatment (arm CT) and only surgery treatment (arm ST). At the time of surgery, patients were classified regarding whether they were subjected to CS (arms CS-CT and CS-ST) or PS (arms PS-CT and PS-ST).
A general diagram of the treatment was previously published 16 and the corresponding CONSORT 23 diagram is depicted in Figure 1a . Patients that received the CT (n ¼ 283) were subjected to CS (removal of all visible gross disease, CS, n ¼ 191) or PS (n ¼ 92). The surgical margin of the cavity after tumor removal was infiltrated with SG carrying lipoplexes co-delivered with GCV evenly distributed at multiple sites in the surrounding areas and/ or in the residual tumor mass. After 24 and 48 h following SG plus GCV delivery, patients orally took 400-800 mg of acyclovir according to their weight. Between 5 and 10 days after surgery, patients were clinically controlled and treated once a week for 5 weeks with an SV composed by autologous (n ¼ 157) or allogeneic (n ¼ 126) formolized tumor cells and irradiated living CHO xenogeneic cells producing 20-30 mg of hIL-2 and hGM-CSF. Patients without local disease received only SV: 5 times (5 Â ) weekly, 5 Â biweekly, 5 Â monthly, 5 Â every 3 months and finally every 6 months until relapse or death. Surgery-treated control patients (ST, n ¼ 135), recruited concurrently to treated (CT) patients without receiving additional antitumor treatment, were subjected to CS (n ¼ 93) or PS (n ¼ 43). The treatment schedule is depicted in Figure 1b .
In a weekly basis (5 ), patients with local disease (partially removed tumor, unsafe surgery limits or with post-surgical relapse) received in the remaining tumor or adjacent areas multiple injections of lipoplexes carrying psCMVtk (1-4 mg DNA) co-delivered with GCV (5-20 mg), according to tumor size (about 0.1 mg DNA cm À 2 of surgical margin). Locally responding patients continued with the chronic weekly treatment until disappearance of any evidence of local disease. At this point, they followed the previous scheme. This local treatment was stopped in the case of non-responding patients (local disease progression). The follow-up lasted until the patients' death.
Periodic clinical evaluations were performed every treatment day and were completed by monthly or bimonthly clinical laboratory analysis. Thoracic radiographs and abdominal echographs were done before treatment, and every month or trimester according to the patients' response, and at longer intervals (6 months) in long-term surviving animals. Data about treatment efficacy and toxicity were compared with surgery control patients. The clinical monitoring of this control group was performed at least every 4 weeks (by the same professionals managing the treatment).
Tumor response criteria
Tumor responses were classified as: complete remission (CR), macroscopic disappearance of the tumor; partial remission (PR), reduction of tumor volume higher than 50%; stable disease (SD), stabilization or increase in tumor volume o50% for at least 45 days after starting treatment; progressive disease (PD), increase of tumor volume 450%. Assessment of clinical response has taken into account all measurable lesions. Only CR and PR were used to determine objective response rate. CR, PR and SD were included to determine tumor control rate. Tumor volume (evaluated by caliper measuring three diameters) was calculated as 4/ 3 Â p Â r 1 Â r 2 Â r 3 .
Quality of life
Evaluation was based on the owner's response to a questionnaire completed before every treatment session. The answers about the different aspects were scored: 1 ¼ worse, 2 ¼ no change and 3 ¼ better compared with the pre-disease state. For the sake of simplicity, values scored 2 or 3 were considered as a positive effect on the quality of life.
Statistics
Disease-free, metastasis-free and overall median survivals were calculated by Kaplan-Meier analysis and curves were compared by Log-rank test. Responses values were compared by two-tail Fisher's Exact test.
RESULTS

Patients' demographics
The CT group was subjected to surgery plus SG combined with an SV composed of cytokines secreting xenogeneic cells. 16 The control group of surgery-treated patients (ST) was composed by patients whose owners decided to proceed only with a surgical intervention under our periodical clinical surveillance.
As depicted in Table 1 , the patients' median ages were between 10 and 12 years. The control ST group as a whole was slightly but significantly older than the treated CT group, as was the males' subgroup with respect to the females' one.
The most represented breeds in ST and CT patients were respectively (Table 1) : Cocker Spaniel (10 and 13%), Doberman Pinscher (6 and 6%), German Shepherd (10 and 10%), Pekingese (11 and 5%), Rottweiler (4 and 6%) and Schnauzer (4 and 3%). The largest part of the patients belonged to mixed breeds (35 and 37%) and other varied breeds (24 and 22%). There were no significant differences in the proportions of the major breeds in the different arms.
All ST and CT dogs (81 and 75% oral, 14 and 15% digital, 2 and 3% ocular, 1 and 3% anal, and 1 and 1% mammary melanoma) were completely staged. The majority of dogs were classified as stage III (46 and 49%, primary tumors X4 cm diameter without metastasis or any size of primary tumor with lymph-node metastasis) or stage I-II (44 and 42%, primary tumors o4 cm diameter and negative proximal lymph nodes). About 10% of patients belonging to ST or CT groups bore lung metastases at the beginning of the trial (Table 1) . No significant differences were found in the proportions of the stages in the different arms.
The CT controlled the local disease Because of the advanced stage of the disease when entered the protocol, about 32% of the patients were subjected to partial tumor resection (PS). In patients experiencing complete tumor resection (CS), CT diminished local relapse (LR) to about one third of the proportion found for surgery controls (Table 3) .
In those patients bearing tumor due to PS (32%) or post-surgical LR (28%), weekly application of CT with additional serial SG therapy induced a substantial local antitumor response. This was evidenced by 62% of the patients presenting objective responses in the CS arm and 47% in the PS arm ( Table 2 ) that averaged 85% of tumor mass loss after five rounds of SG plus GCV treatment as already reported. 16 At this point, tumors were treated with SG less frequently: every 14, 28 or 56 days, until they resolved or were judged to become unresponsive because of tumor progression.
No significant differences were found in the relative amount of response types to local SG transfer (except for PD Po0.001). However, the median durations of responses were significantly higher in CS arm compared with PS ( Table 2) .
The objective responses to CT resulted higher in patients with smaller tumors as already reported. 16, 20 While 24% of CS and 32% of PS patients displayed SD, 13% of CS and 22% of PS patients displayed tumor progression. It is noteworthy that the treatment of the surgical margins with SG plus GCV had a critical role in avoiding LR in 72% of the CStreated patients in the CT arm, while only 13% of the CS treated of the ST arm did so (Table 3) .
Taken together, CT patients that did not display post-surgical LR (72%) plus those that attained a complete response (CR) to the SG (8% of total CT), resulted in 81% of patients free of local disease, where 65% of them died or were still alive without any evidence of disease at the end of the study.
Due to the periodic modality of the local treatment, the median number of intra/peritumoral applications (Table 2) varied according to the response rate from 6 (range: 5-15), in the case of CR after treating LR in the CS arm, to 12 in the case of SD in both arms (LR range: 5-15, PS: range 6-14).
The CT controlled the systemic disease The CT succeeded in controlling the systemic disease as evidenced by the significantly higher percentage of metastasis-free CT patients at the end of the study (CS: 84% and PS: 82%), compared with ST (CS: 32% and PS: 71%). The apparently high percentage of PS-ST metastasis-free patients (71%) was due to the fact that at the median onset of the metastasis (79 days, range 10-131), most of the patients were already dead (overall survival: 66 days, range 29-159) ( Table 4) . It is worth to note that CT augmented fivefold the fraction of metastasis-free patients with respect to those bearing distant metastasis (Po2 Â 10 À 17 , Fisher's Exact test). These two sets were not significantly different in the PS arm (Table 3) .
A very encouraging outcome was the CR of distant non-injected metastases already present when three stage IV patients were recruited for the trial. One case was related to multiple liver metastases and two cases to lung metastases (data no shown).
The CT significantly prolonged patients' survival As derived from Kaplan-Meier analysis, the CT resulted in a sevenfold (CS) and threefold (PS) increase in overall survival compared with their respective surgery controls ( Figure 2 ; Table 4 ). If we consider as statistical event the death caused by Metastases location at the end of the treatment.
Adjuvant combined gene therapy for canine melanoma LME Finocchiaro et al In all, 145 patients out of 283 (those subjected to PS or those presenting LR after complete surgery) were clinically evaluated and treated on a weekly basis with intratumor injections of lipoplexes carrying the suicide gene (SG) system concurrent with the cytokine-secreting xenogeneic subcutaneous vaccine as described in Materials and methods. ORs and SD were considered until they turned into PD or death (whichever came first) while non-responding PD duration was considered from the beginning of the treatment until the death of the patient. Values were derived from Kaplan-Meier analysis (plots not shown). Median duration of SD was significantly lower than median duration of OR (Po0.0001).
P-values were calculated by Log-rank test for Kaplan-Meier analysis. Median # of SG: median number of suicide gene. Table 3 . Disease status at the end of the study and causes of death melanoma, and no event the dead due to unrelated causes, then the survival curve stays over 50% beyond 2848 days (7.8 years), precluding the calculation of the median survival. This evidenced a dramatic increase of CT patients survival expectation 429-fold compared with ST (Table 4) . On the other hand, PS-CT patients overall survival to melanoma resulted in fourfold higher than the corresponding PS-ST controls. The CT dramatically increased the disease-, recurrence-and metastasis-free survival of the CS arm, and the metastasis-free survival of the PS arm ( Figure 3 ; Table 4 ). The respective curves stayed over 80% beyond 2848 days (7.8 years) and 952 days (PS: 2.6 years) precluding the calculation of the median survival.
In addition, the survival until progression of first event, local and metastasis in CT patients were significantly higher (CS: about 38-, 15-and 16-fold; PS about 5-, 5-and 7-fold) than the respective values for ST patients (Tables 4 and 5 ).
As seen in Table 5 , CS-CT patients displayed significantly higher overall survival (to any causes) than PS-CT. A similar pattern Figure 2 . Kaplan-Meier analysis of overall survival. Overall survival due to any cause (AC) or melanoma (M) for patients subjected to complete (CS, a) or partial (PS, b) surgery was censored as described in Table 6 . ST, only surgery treatment controls; CT, combined treatment. Abbreviations: CT, combined treatment; NS, no significant; ST, only surgery treatment.
Overall survival due to any cause: all deceased patients were censored as event for Kaplan-Meier analysis.
Overall survival due to melanoma: patients that died because of causes unrelated to melanoma progression were censored as alive (no event) the day of death (Figure 2 ). Disease-free survival: from Kaplan-Meier analysis (Figure 3 ), patients were censored as disease free until the first event (local recurrence or metastases). Both living and dead patients that developed local recurrence or metastases were considered. Patients that have never developed local recurrence or metastases were censored as disease free the day of death. Recurrence-free survival and metastasis-free survival were computed analogously. Survival until progression: From Kaplan-Meier analysis. Median time until late disease progression (first event, recurrence or distant metastasis) or separately to recurrence and metastasis (plots not shown). At this stage, the disease was unable to be controlled by the combined treatment.
appeared when comparing survival until progression (first event and local). However, no significant differences between recurrence-free and local recurrence subgroups appeared in overall survival (to any causes), as happened with survival until metastasis progression.
The median number of periodical SV applications was slightly but significantly higher (Po0.0001) for patients subjected to CS (17, range 6-29) with respect to PS (15, range 5-22) ( Table 5) .
As expected, CS-CT median overall survival was significantly higher in younger patients up to10 years old, while there were no significant survival differences between 1-10 years and 11-18 years in PS-CT and ST (CS and PS) controls (Table 6 ).
As derived from Kaplan-Meier analysis, the fact that some patients received autologous (n ¼ 108, 57%) or allogeneic (n ¼ 83, 43%) vaccine did not significantly affect the overall survival (due to melanoma or to any cause; Table 7 ).
Because of their advanced age and the remarkable increase in median overall survival, 60% of deceased patients subjected to CS-CT died of unrelated causes, most of them free of melanoma disease (7% of patients died of a secondary malignancy), while 40% died or were humanely euthanized because of local tumor (26%) or metastases (15%) progression. Conversely, the pattern resulted significantly different for deceased patients belonging to CS-ST group: 99% dying Table 6 . CT, combined treatment; CS, complete surgery; PS, partial surgery; ST, only surgery treatment. Overall survival due to any cause (DAC): all deceased patients were censored as event for Kaplan-Meier analysis.
Overall survival due to melanoma (DM): patients that died because of causes unrelated to melanoma progression were censored as alive (no event) the day of death (Figure 2 ). Survival until progression: From Kaplan-Meier analysis. Median time until late disease progression (first event, recurrence or distant metastasis) or separately to recurrence and metastasis (plots not shown). At this stage, the disease was unable to be controlled by the combined treatment. P-values were calculated by Log-rank test for Kaplan-Meier analysis.
because of melanoma (50% local tumor and 49% metastases progression) (Table 3 ). In the case of PS, while only 10% of the CT treated died of unrelated diseases, none of the ST patients did so. It is worth to note that after more than a 9-year follow-up period, 21% of the CS-CT and 12% of the PS-CT treated patients abandoned the treatment and 10 and 5% respectively are still alive, nearly all of them with no evidence of disease and long exceeding dead patients' survival. Most of the 34 still alive patients were long-term survivors: 1 47 years, 5 43 years, 7 42 years and 15 41 year. In addition, among the 70 dogs that abandoned the trial, 2 did it after 5 years, 2 after 4 years, 8 after 3 years, 6 after 2 years and 10 after 1 year.
The treatments resulted innocuous Toxicity was minimal or absent in all dogs. Repeated injections into the tumor bed of SG plasmid DNA:DMRIE/DOPE lipoplexes, as well as subcutaneous administration of cytokine-secreting xenogeneic cells, resulted safe, not allergenic, and could be applied repetitively. Minor side effects were registered in some patients and can be classified as grade p1 following the VCOG-CTCAE criteria. 24 They typically involve necrosis (44%) and a vitiligo-like tumor de-pigmentation at the sites of SG injection (23%) as well as edema (33%), swelling and itching (14%) at the injection places and indurations (11%), after SV application. Neither significant changes in clinical and hematological parameters, nor local or systemic toxicity, nor organic dysfunction or fever during or at the completion of the study could be attributed to treatment.
The proposed CT significantly restored the patients' quality of life to the pre-disease state, as regularly reported by the owners: improving vigor (in 57% of cases), activity (74%), mood (94%), appetite (91%), alert state (78%), general welfare (75%) and clinical condition (89%). This effect lasted as long as the disease was stable or regressing and it was abolished after advanced relapse and disease progression. General welfare was periodically interrupted by 24-48 h by transient mild flu-like symptoms (25%) that often followed by a local treatment application. Recovery from surgery usually took 12-36 h.
DISCUSSION
In the first report of this open-label controlled study comprising 4100 dogs with canine malignant melanoma, we demonstrated that a surgery adjuvant treatment that combined (i) the local antiproliferative effects of SG therapy with (ii) the systemic effects triggered by canine melanoma antigens in an immunostimulatory environment created by the slow secretion of hGM-CSF and IL-2, substantially prevented or delayed LR, regional and distant metastases, and improved disease-free and overall survival in the treated animals compared with surgery-treated controls. 16 Here, we present updated results at 9 years from the beginning of this study, confirming our approach as a successful strategy that offers several advantages. First, we co-delivered lipid-complexed SG with GCV increasing the local concentration of the prodrug that will be readily available for the expressed enzyme. 16, 20 In addition, the small size of the plasmid vector (psCMV, 3.3 kb) facilitated its lipofection efficiency both in vitro and in vivo. 16, [18] [19] [20] Second, the surgical margin of the cavity after tumor removal was infiltrated with lipid-complexed SG co-administrated with GCV evenly distributed at multiple sites in the surrounding areas and/or in the residual tumor mass. This new SG-generated margin had a critical role delaying (from CS-ST: 47 days, range 3-425, n ¼ 81 to CS-CT: 154 days, range 27-769, n ¼ 53) or abolishing LR in 72% of the CT patients (Table 4) .
Third, intra-tumor injections of lipid-complexed SG could interact with the state of tumor-mediated tolerance and immunosuppression promoting a higher immune response against a broader array of tumor antigens, finally leading to an inhibition of tumor growth or tumor rejection. 16, 25 Furthermore, cationic lipids and plasmid DNA immunostimulatory sequences might increase tumor immunogenicity. 26, 27 Thus, in those patients with local disease due to PS or post-surgical relapse, SG therapy, sustained by the SV, elicited a powerful antitumor synergy evidenced by: (i) a significant number of CS and PS patients presenting objective responses (62 and 47%, respectively); and (ii) the significantly increased fraction of CS patients free of local disease (81 and 14%, respectively, with respect to 13 and 0% of surgery-treated controls).
Fourth, as a co-adjuvant of SG therapy and to boost the antimelanoma immune response, a subcutaneous autologous or allogeneic vaccine (SV) enhanced by the local slow and sustained release of hIL-2 (refs. 28, 29) and hGM-CSF [30] [31] [32] was administered. 16, [18] [19] [20] These whole tumor cell vaccines have the advantage of immunizing the patient with a broader array of tumor-associated antigens, increasing the likelihood of effective immunostimulation. 16, 20, 32 In addition, the repeated induction of a potent localized immune stimulus by xenoantigens, together with the secretion of cytokines by engineered xenogeneic cells, would be able to elicit a powerful systemic antitumor response. Evidence of SV efficacy was the remarkable increase in the percentage of metastasis-free CT patients at the end of the study (CS: 84% and PS: 82%), compared with their respective CS-ST controls (32 and 71%). The apparently high percentage of PS-ST metastasis-free patients (71%) was due to the fact that at the median onset of the metastasis most of the patients were already dead (Table 4) .
Fifth, the three approaches (IL-2 and GM-producing engineered cells, and HSVtk/GCV SG therapy) were clinically assayed before, but primarily as monotherapy and yielding relatively poor outcomes. 6, 7, 29, 31, 33 Our updated study suggests that trials combining these strategies appear to be considerably superior to each monotherapy. The basis of CT clinical efficacy was the induction of an effective local and systemic antitumor response. This was strongly supported by the highly significant (PE0, Fisher's Exact test), number of CS-CT patients local disease free (154, Po3.5 Â 10 ) compared with the respective of CS-ST (12; 5 and 30) . Even though the PS-CT was less effective than the CS-CT to control the disease, it was significantly better than only surgery (PS-ST: Po0.01 Table 4 and CS-ST: Po0.05, Fisher's Exact test). Thus, this updated study suggests that this CT holds the most promise for cancer patients with minimal residual disease, [6] [7] [8] 16, 20 and corroborates the negative prognostic factor for the presence of local disease that substantially shortened patients median overall survival (Tables 4 and 5) .
Sixth, even though the slightly lower median ages of the CS-CT group (P ¼ 0.03) could favor its overall survival, this cannot explain the high increase in overall survival of this group with respect to CS-ST group for a very fast progressing disease-like melanoma (Figure 2 ; Table 4 ). In fact, there were no significant survival differences between 1-10 years and 11-18 years of ST controls. Conversely, as expected, in the treated CS-CT group younger patients displayed significantly longer survivals than older patients (Table 6) .
Seven, the most stimulating outcome was the dramatic increase in disease-free patients and overall survival (Figures 2 and 3 ; Table 3 ). Compared with surgery control patients, the treatment produced a significant sevenfold (CS) and threefold (PS)-increase in overall survival. However, because of their advanced age and the remarkable increase in median overall survival, 60% of deceased patients subjected to CS-CT died of melanoma unrelated causes. Then, as demonstrated above, survival expectation could be higher in younger patients. When only the death caused by melanoma was considered as statistical event, the CS-CT median survival curve stayed over 50% beyond 2848 days (7.8 years). This evidenced a dramatic increase in CT patients survival expectation 429-fold compared with ST ( Table 4 ). The CT also dramatically increased the disease-and recurrence-free survival of the CS arm ( Figure 3 ; Table 4 ). Similar results were obtained on metastasis-free CT survival where the PS and CS respective curves also stayed over 80% beyond 2848 days (7.8 years) and 952 days (2.6 years), suggesting that 480% of the CT (CS and PS) patients would never develop metastasis ( Figure 3 ; Table 4 ). In addition, the median survival until first event or local progression of patients with complete tumor resection (with or without local recurrence) were substantially greater than those of dogs with partial tumor resection and significantly higher than their respective values for ST patients (Tables 4 and 5 ). Thus, even in the case of a new round of disease progression, the CT could significantly delay and/or slow down its evolution.
Thus, we can assume that the CS-CT treatment could transform a lethal disease into a chronic one in such a way that more of 50% of our patients died of melanoma unrelated causes. The latest hypothesis was strongly supported by the following facts: (i) younger CS-CT patients displayed significantly longer survivals (Table 7) and (ii) the number of CS-CT patients that died of melanoma unrelated causes was so different from their respective CS-ST that the possibility of being just a product of hazard was almost zero (Po8 Â 10 À 22 , Fisher's Exact test; Table 4 ). Eight, to be accepted for clinical practice, any new cancer therapy should not only increase the survival lapse but also improve the quality of life. There is an increasing number of emerging new drugs for human metastatic melanoma like vemurafenib, 34 a BRAF kinase inhibitor, and ipilimumab, 35 an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4. These drugs were able to increase overall survival for a narrow subset of melanoma patients, but presented a high rate of adverse events.
Ninth, in opposition to other highly toxic therapies our proposed treatment could contribute in both ways. In addition to extend survival, it significantly restored the patients' quality of life improving general welfare and clinical condition.
The safety and efficacy of this treatment are supported by: (i) a high number of patients in the CT arm (283), (ii) 49 years of follow-up and (iii) long-term surviving patients that were periodically treated for many years. This is very relevant, given the high lethality of this tumor, and because it demonstrates the absence of side effects by prolonged use.
Taking into account the high number of patients involved in this veterinary clinical trial, one of the major strengths of this work is the very high level of significance (PE0) in the comparison of different outcomes between non ST and CT arms as derived from Fisher's Exact test: (i) general and local disease free vs disease bearing; LR vs no LR and metastasis free vs metastasis bearing and (ii) disease vs unrelated diseases (Table 3) .
In conclusion, the use of this treatment after surgical removal of the tumor is safe and could delay or prevent post-surgical recurrence and metastases, with the consequent quality of life and survival rate improvement. As far as we know, this is the largest veterinary cancer gene therapy clinical trial ever reported: its successful outcome encourages its immediate application in veterinary clinical oncology. Furthermore, the results presented here could serve as preclinical proof of concept and long-term safety data supporting the further translation of similar approaches to clinical trials for HM.
